TMCnet News
AskBio Appoints Anna Tretiakova, PhD, as Senior Vice President of Product DevelopmentRESEARCH TRIANGLE PARK, N.C., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that it has appointed scientific leader Anna Tretiakova, PhD, as Senior Vice President of Product Development. Reporting to Jude Samulski, PhD, Chief Scientific Officer and co-founder of AskBio, Anna will lead the company’s research and translational collaborations to deliver clinical candidate vectors. An industry veteran with more than 30 years of research and development and translational medicine experience, Dr. Tretiakova has spent nearly 10 years exclusively focused on AAV gene therapy at the University of Pennsylvania Gene Therapy Program, Pfizer Rare Disease Research Unit and, most recently, SwanBio Therapeutics. “Broadening our research and development team is critical to achieving our mission to transform genetic medicine, and we are excited to add Anna’s expertise moving AAV programs into the clinic,” said Dr. Samulski. “She will lead preclinical translational research across all of our existing and future therapeutic areas to ensure we pursue the highest quality candidates for clinical development.” “Throughout my career, I have been inspired to help patients with untreatable diseases,” said Dr. Tretiakova. “I am thrilled to join AskBio to help advance our preclinical programs with safety and speed and drive down the cost to make gene therapy available o all who need it.” In addition to delivering clinical candidate vectors into the therapeutic programs, Dr. Tretiakova will be part of AskBio’s leadership team tasked with driving value across the integrated gene therapy technology platforms. She continued, “AskBio has one of the most impressive visions for gene therapy and has undertaken a fully integrated strategy to advance DNA and vector manufacturing, capsid and gene cassette engineering, knowledge of vector biology and immunology to allow for treatment re-administration, and tissue targeting. All of this is done within one company, which is unprecedented in the gene therapy industry today.” About Anna Tretiakova, PhD She completed her graduate education in molecular biology and biochemistry with a PhD from Thomas Jefferson University in Philadelphia and diploma from Novosibirsk State University in Russia. About AskBio Contact: Robin Fastenau Vice President, Communications +1 984.275.2705 [email protected] |